global-women-health-orthopedics-congress-2018-posters

3 / 22

Page 35
S e p t e m b e r 0 6 - 0 7 , 2 0 1 8 | B a n g k o k , T h a i l a n d
Note:
alliedacademies Joint Event on
Global Women Health 2018 & Orthopedics Congress 2018 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 2
BREAST CANCER, GYNECOLOGY AND WOMEN HEALTH
ORTHOPEDICS AND RHEUMATOLOGY
&
World Congress on
Annual Conference on
Subhan Arif Rahman et al., Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C3-009
THERAPEUTIC RESPONSE AND SIDE EF-
FECTS OF CHEMOTERAPHY COMBINATION
REGIMEN BETWEEN PACLITAXEL-CISPLA-
TIN AND PACLITAXEL-CARBOPLATIN ON
CERVICAL CANCER STAGE IIB
Subhan Arif Rahman, Sharvianty Arifuddin, Nusratuddin
Abdullah, Maisuri T Chalid, Nugraha U P and Effendi Lukas
Hasanuddin University, Indonesia
Background: To compare therapeutic response and side effects of
chemoteraphy combination regimen between paclitaxel-cisplatin and
paclitaxel-carboplatin on cervical cancer stage IIB.
Methods: 32 patients with stage II B cervical cancer that diagnosed by
physical examination and CT scans were included in the study. Chemotherapy
combination regimen paclitaxel 175 mg/m2 and cisplatin 50 mg/m2 in group
one (16 patients) compared with paclitaxel 175 mg/m2 and Carboplatin 300
mg/m2 in group 2 (16 patients). The tumor volume was measured in three
dimensions with computed tomography scan (CT scan) before and after six
cycles. Clinical response is evaluated by physical examination.
Result: The average tumor volume decreases significantly (73.41% vs. 75.65%
in groups 1 and 2, respectively, P=0.001), complete response rate (25% vs.
31.2%), and partial response (62.5% vs. 56.2%), progressive response rate
(12.5% vs. 6.2%), with p>0.05 which means no significant differences on
complete response rate, partial response rate and progressive response rate
between groups of carboplatin nor cisplatin group. Class three toxicity (CTC
criteria) were more dominant in the cisplatin group, nausea and vomiting
(12.5%), and hematologic grade three grade hematologic toxicity symptoms
in both groups (12.5% vs. 12.5%)
Conclussion: Chemotheraphy combination regimen of paclitaxel-carboplatin
proved to be more effective in reduction of tumor size with fewer side effects
compared to the paclitaxel-cisplatin combination regimen in stage IIB cervical
cancer.